LR Health & Beauty SE: Preliminary Results For Financial Year 2025, Target Equity Contribution, and Targeted Restructuring of the 2024/2028 Bonds.
Ahlen, Germany – Based on the preliminary financial results for the financial year 2025, the Management Board of LR Health & Beauty SE (the “Company”) now expects an EBITDA* reported of around EUR 16 million for the financial year 2025 (previously expected to be between EUR 17.0 million and EUR 20.0 million). At the same time, the Management Board of the Company expects sales (revenue from goods sold) of around EUR 277 million for the full year 2025 (previously expected to be between EUR 276 million and EUR 281 million).
Also today, EY-Parthenon announced the completion of a draft IDW S 6 restructuring opinion in respect of the Company. Pursuant to the analysis set out in that draft restructuring opinion, the Company will for the financial year 2028 achieve an EBITDA* of EUR 27.3 million and sales of EUR 281.5 million in the sensitivity case, and an EBITDA* of EUR 31.4 million as well as sales of EUR 284.7 million in the management case.
Against this background, the Company decided today to enter into discussions with its shareholder and with the bondholders of the